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In the early 2000s, the pages of medical
journals were filled with (often rancorous)
debates about the feasibility and prudence
of expanding access to antiretroviral
therapy (ART) in sub-Saharan Africa,
where HIV disease had become the
leading cause of death among young
adults. Despite a paucity of supporting
data, some public health experts warned of
‘‘antiretroviral anarchy’’ in Africa and the
resulting spread of poly-resistant strains of
HIV to wealthy countries [1,2,3].
Shortly after HIV treatment scale-up
began in earnest across the continent,
however, adherence to ART in Africa was
found to be significantly higher than in
North America [4]. As more patients
initiated therapy, it was thus expected that
the wide outcome gaps between the two
settings would narrow.
In a landmark analysis of data from
67,354 patients in this week’s issue of
PLOS Medicine, Andrew Boulle and
colleagues report that all-cause mortality
rates among South African patients on
ART for longer than 24 months have
fallen to levels equal to or below those
registered in comparable North American
cohorts [5]. Among patients with timely
and sustained access to care and for whom
data was available, the same proportion as
in Europe (89.5%) achieved virological
suppression to below 400 copies/ml after 6
months on treatment in South Africa,
compared to 73.4% in North America [5].
With more than 2.5 million South
Africans on effective treatment (increas-
ingly financed by the national govern-
ment), the country is now beginning to
rein in the world’s largest HIV epidemic
[6]. Over the same period as Boulle and
colleagues’ study, the scale-up of ART in
rural Kwa-Zulu Natal was associated with
an overall gain of 11.3 years of adult life
expectancy between 2003 and 2011 [7].
The study also highlights the crucial
role of population-based registries in
identifying and redressing disparities.
More than half of the deaths included in
the South African analysis were missed by
cohort studies but captured by the national
vital registry [5]. In settings with weak or
absent registries, clinic-based efforts to
ascertain long-term patient outcomes
may underestimate mortality.
In line with earlier comparative analyses
[8], Boulle and colleagues’ study shows
that early mortality (within the first 12
months of therapy) remains very high in
South Africa, at 9.7%—more than double
that in North America (4.6%) and nearly
five times that in Europe (2.0%) [5]. While
poor long-term outcomes in North Amer-
ica appear to be linked to poor retention in
care among marginalized groups, subop-
timal adherence, and the impact of highly
prevalent co-infections such as chronic
viral hepatitis C, the most important
driver of mortality in South Africa was
delayed access to care: half of South
African participants had a CD4 count
below 100 cells/ml when they initiated
treatment [5].
One in seven patients in the South
African studies was lost to follow-up [5].
As noted, linking such patients with
national death registries is an important
task for researchers and epidemiologists,
but closing remaining equity gaps will
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care—keeping them in the cohort and off
of the registry. North America and South
Africa each had a cumulative incidence of
mortality that exceeded Europe’s by more
than 300% in the study; vulnerable
patients continue to fall through the
cracks.
Barriers related to poverty, stigma, and
race exist along each step of the care
continuum for HIV [9]. For example, the
advent of highly effective direct-acting
antiviral regimens could open the door to
substantial improvements in long-term
survival in the United States among
patients co-infected with HIV and viral
hepatitis C. Realizing such gains, however,
would require an effective delivery strategy
that guarantees access and assists patients
in overcoming major barriers to treatment
adherence and retention in care [10].
While challenges related to the delivery
of care vary widely across contexts, it is
possible that certain lessons—especially
pertaining to community-based care—
learned in rural South Africa or central
Haiti might offer a promising way forward
for improving treatment outcomes for
HIV and other chronic diseases in North
America [11].
Rigorous ethnographic studies have
revealed structural barriers, such as food
insecurity and high transportation costs, as
major contributors to loss to follow-up
among poor patients, regardless of where
they live [10,12]. As we have noted
elsewhere, when taking average family
incomes into account, a monthly round-
trip bus fare to refill an ART prescription
can pose a similar burden in rural Africa
as a monthly business class airplane ticket
from Los Angeles to Boston in the US
[13]. Sustained reductions in mortality will
require investing in approaches to
strengthening health systems that support
patients in overcoming these obstacles,
and that harness the social capital shown
to facilitate adherence [14].
And what of the many hundreds of
thousands of would-be patients who never
begin therapy at all? Flat-lined global
resources have hamstrung the AIDS
response in many settings around the
world, and reports of waiting lists for
ART have grown increasingly common in
Africa in recent years [15].
Disparities of access and outcome that
are both regional and intensely local in
nature warrant a substantial increase in
attention in each of the settings studied. In
the US, residents of the District of
Columbia are 12 times more likely to die
of HIV than those in the neighboring state
of Virginia [16]. Deaths due to HIV
disease have risen 15-fold since 2000 in
Eastern Europe; the AIDS-related mortal-
ity rate in Ukraine now exceeds that in
Ethiopia and Burkina Faso [17]. In Africa,
27 nations have less than 40% coverage
for ART under the latest World Health
Organization guidelines [6].
When access is assured and sustained, it
is now clear that excellent clinical out-
comes are possible, including (or, perhaps,
especially) in rural regions of Africa. Far
from wishful thinking, the notion of a
‘‘grand convergence’’ in global health
through the narrowing of disparities across
continents and income groups is both a
concrete possibility and a moral impera-
tive, achievable with accelerated commit-
ments and committed partnerships in all
settings [18].
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